MedTrace Logo

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

NCT02300870 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-07-27

No results posted yet for this study

Summary

The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term outcomes.

Conditions

  • Heart Transplantation

Interventions

DRUG

Optison

Echocardiogram with IV contrast

Sponsors & Collaborators

  • General Electric

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Michael Givertz, MD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300870 on ClinicalTrials.gov